The stock of Actinium Pharmaceuticals Inc (ATNM) has gone up by 17.04% for the week, with a -13.66% drop in the past month and a 29.51% rise in the past quarter. The volatility ratio for the week is 6.43%, and the volatility levels for the past 30 days are 8.18% for ATNM. The simple moving average for the past 20 days is 3.98% for ATNM’s stock, with a 8.40% simple moving average for the past 200 days.
Is It Worth Investing in Actinium Pharmaceuticals Inc (AMEX: ATNM) Right Now?
ATNM has 36-month beta value of -0.54. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ATNM is 30.40M, and currently, short sellers hold a 4.72% ratio of that float. The average trading volume of ATNM on July 10, 2025 was 367.66K shares.
ATNM) stock’s latest price update
Actinium Pharmaceuticals Inc (AMEX: ATNM)’s stock price has soared by 10.49% in relation to previous closing price of $1.43. Nevertheless, the company has seen a gain of 17.04% in its stock price over the last five trading days. prnewswire.com reported 2025-06-23 that – ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination – ATNM-400 is more efficacious than both Pluvicto® (177-Lu-PSMA-617) and Ac-225-PSMA-617 targeted radiotherapy in prostate cancer in vitro and in vivo models and overcome resistance in prostate cancer tumors that failed Pluvicto® therapy – ATNM-400’s target is highly differentiated from PSMA as it is implicated in disease biology, contributing to disease progression, faster progression to castration resistance and poorer survival outcomes with target expression reported following androgen receptor inhibitor and PSMA radiotherapy – Data further supports ATNM-400’s potential to address critical gaps in prostate cancer treatment as a monotherapy or in sequence with other therapeutic modalities NEW YORK, June 23, 2025 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today reported new preclinical data from its first-in-class, non-PSMA targeting radiotherapy prostate cancer candidate ATNM-400, that leverages the potent alpha-particle emitter Actinium-225 (Ac-225) isotope, at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting being held June 21 st – 24th, 2025, in New Orleans, Louisiana. The data presented at SNMMI showed ATNM-400 has superior potency compared Xtandi® (enzalutamide) and is highly efficacious in Xtandi® resistant prostate models.
Analysts’ Opinion of ATNM
Many brokerage firms have already submitted their reports for ATNM stocks, with B. Riley Securities repeating the rating for ATNM by listing it as a “Neutral.” The predicted price for ATNM in the upcoming period, according to B. Riley Securities is $2 based on the research report published on August 07, 2024 of the previous year 2024.
Stephens, on the other hand, stated in their research note that they expect to see ATNM reach a price target of $25. The rating they have provided for ATNM stocks is “Overweight” according to the report published on May 14th, 2024.
HSBC Securities gave a rating of “Buy” to ATNM, setting the target price at $11.60 in the report published on September 06th of the previous year.
ATNM Trading at 1.14% from the 50-Day Moving Average
After a stumble in the market that brought ATNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.71% of loss for the given period.
Stock Fundamentals for ATNM
The total capital return value is set at -0.8. Equity return is now at value -130.87, with -57.98 for asset returns.
Based on Actinium Pharmaceuticals Inc (ATNM), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -23.22.
Currently, EBITDA for the company is -37.43 million with net debt to EBITDA at 1.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.35.
Conclusion
To put it simply, Actinium Pharmaceuticals Inc (ATNM) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
